Biological effects of pramipexole on dopaminergic neuron-associated genes: relevance to neuroprotection
- 29 March 2005
- journal article
- research article
- Published by Elsevier in Neuroscience Letters
- Vol. 377 (2) , 106-109
- https://doi.org/10.1016/j.neulet.2004.11.080
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Neuroprotection in Parkinson DiseaseJAMA, 2004
- Dopamine agonists in Parkinson’s diseaseExpert Opinion on Investigational Drugs, 2003
- Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonistsNeurotoxicity Research, 2003
- Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease ProgressionJAMA, 2002
- Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotectionJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2000
- Pramipexole vs Levodopa as Initial Treatment for Parkinson DiseaseJAMA, 2000
- Reduced Nurrl Expression Increases the Vulnerability of Mesencephalic Dopamine Neurons to MPTP‐Induced InjuryJournal of Neurochemistry, 1999
- Pramipexole — a new dopamine agonist for the treatment of Parkinson's diseaseJournal of the Neurological Sciences, 1999
- Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neuronsProceedings of the National Academy of Sciences, 1998
- Uptake of a neurotoxin-candidate, (R)-1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline into human dopaminergic neuroblastoma SH-SY5Y cells by dopamine transport systemJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1994